For years, CRISPR Therapeutics (NASDAQ: CRSP) has been the type of stock investors might call a home run swing.
The company develops medicines using gene-editing technologies to treat or cure serious conditions and diseases that traditional pharmaceutical drugs cannot
The stock has generated good returns over time, but it’s been a very bumpy ride at times. Today, CRISPR Therapeutics’ stock trades at a fraction of its former price. However, Wall Street analysts see opportunity.
On CNN Business, 58% of Wall Street analysts have rated CRISPR Therapeutics as a buy, with price targets signaling as much as 437% upside. Here’s a look at why analysts might be bullish. Commercial revenue is finally taking off CRISPR Therapeutics has been around for years, but it only recently commercialized its first product.